Could a monthly shot beat biweekly for lowering cholesterol?

NCT ID NCT07712042

Not yet recruiting Disease control Sponsor: Mei Gao Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study looks at two different dosing schedules of the drug tafolecimab—given every two weeks or every three weeks—in people with high cholesterol that isn't controlled by statins alone. Over 12 weeks, researchers will measure how much LDL (bad) cholesterol drops and how safe each schedule is. The goal is to see if a less frequent injection works just as well.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tafolecimab, an injectable PCSK9 inhibitor
What this could lead to: If successful, this could help identify a more convenient dosing schedule for tafolecimab, making it easier for patients to manage high cholesterol.
What could go wrong: This is a small, observational study without randomization, so results may be less reliable. The 12-week follow-up is short, and long-term benefits or risks are not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERLIPIDEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Qianfoshan Hospital

Ji'nan, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.